Literature DB >> 15379739

Epidemiology of restless legs in The Netherlands.

Roselyne Rijsman1, Arie Knuistingh Neven, Willy Graffelman, Bob Kemp, Al de Weerd.   

Abstract

The prevalence of restless legs syndrome (RLS) in various regions in the world has been estimated between 2.5 and 29%. For The Netherlands these figures are not known. Our observational and cross-sectional study was performed to estimate the prevalence of RLS in The Netherlands. A cross-sectional survey by postal questionnaire was carried out through a general practice in a small town in which one general practice serves 93% of the population. All men and women aged 50 years and older were invited to fill out the questionnaire on leg movements, quality of sleep and daytime symptoms. A total of 1485 (88.2%) persons returned their questionnaire and 1437 (85.4%) patients answered the questions on leg movements. A total of 102 (7.1%) inhabitants answered positively to the questions on leg movements and probably have RLS. The prevalence was higher in women and increased with age. People who complain of RLS have significantly more complaints of disturbances in initiating and maintaining sleep, sleepiness, tiredness during the day and less refreshing sleep. RLS is common in The Netherlands with an estimated prevalence of 7.1% in the population over 50 years of age.

Entities:  

Mesh:

Year:  2004        PMID: 15379739     DOI: 10.1111/j.1468-1331.2004.00848.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  16 in total

Review 1.  Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment.

Authors:  Paul Yeh; Arthur S Walters; John W Tsuang
Journal:  Sleep Breath       Date:  2011-10-26       Impact factor: 2.816

2.  Restless legs syndrome: relationship between prevalence and latitude.

Authors:  Brian B Koo
Journal:  Sleep Breath       Date:  2011-12-31       Impact factor: 2.816

Review 3.  Management of restless legs syndrome in patients on dialysis.

Authors:  Miklos Z Molnar; Marta Novak; Istvan Mucsi
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  The prevalence of restless legs syndrome in Edirne and its districts concomitant comorbid conditions and secondary complications.

Authors:  Sibel Güler; Ayşe Caylan; F Nesrin Turan; Nezih Dağdeviren; Yahya Çelik
Journal:  Neurol Sci       Date:  2015-05-20       Impact factor: 3.307

Review 5.  Epidemiology of restless legs syndrome: a synthesis of the literature.

Authors:  Maurice M Ohayon; Ruth O'Hara; Michael V Vitiello
Journal:  Sleep Med Rev       Date:  2011-07-26       Impact factor: 11.609

6.  Prevalence of Restless Legs Syndrome in Patients with Inflammatory Bowel Disease.

Authors:  Ikuko Takahara; Fuminao Takeshima; Tatsuki Ichikawa; Toshihisa Matsuzaki; Hidetaka Shibata; Satoshi Miuma; Yuko Akazawa; Hisamitsu Miyaaki; Naota Taura; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2016-12-29       Impact factor: 3.199

7.  The high prevalence of restless legs syndrome symptoms in liver disease in an academic-based hepatology practice.

Authors:  Rose A Franco; Ramesh Ashwathnarayan; Arshana Deshpandee; Joshua Knox; Jack Daniel; Daniel Eastwood; Jose Franco; Kia Saeian
Journal:  J Clin Sleep Med       Date:  2008-02-15       Impact factor: 4.062

Review 8.  Sleep disorders: a systematic review of an emerging major clinical issue in renal patients.

Authors:  Paul Gusbeth-Tatomir; Daniela Boisteanu; Anca Seica; Catalina Buga; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2007-10-04       Impact factor: 2.370

Review 9.  Restless legs syndrome: pathophysiology, diagnosis and treatment.

Authors:  Pankaj Satija; William G Ondo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Noninvasive neuromodulation reduces symptoms of restless legs syndrome.

Authors:  Mark J Buchfuhrer; Fiona C Baker; Haramandeep Singh; Viktoriia Kolotovska; Bahman Adlou; Harnadar Anand; Massimiliano de Zambotti; Mehvish Ismail; Shriram Raghunathan; Jonathan D Charlesworth
Journal:  J Clin Sleep Med       Date:  2021-08-01       Impact factor: 4.324

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.